Articles From: Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes to Aben Resources Closes $102,000 Flow Through Financing


- FreeStyle Libre System eliminates routine finger pricks for glucose measurements1 and requires no finger pricks for calibration - Available for people living with diabetes in several European markets beginning in the coming weeks - Advanced Ambulatory Glucose Profile software presents data in a user-friendly, visual chart, enabling productive treatment discussions ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes investment picks
ABBOTT PARK, Ill., June 24, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in Europe for the TECNIS ® Symfony Extended Range of Vision intraocular lens (IOL) for the treatment of cataract patients who may also have a diminished ability to focus on near objects (presbyopia). Standard IOLs can be used in cataract treatment to improve distance vision, but the TECNIS Symfony IOL is a first-of-its kind lens that is intended to provide patients a continuous range of vision including far, intermediate and near distances with reduced incidence of halo and glare comparable to a monofocal lens 1 .
Sign-up for Abbott Receives CE Mark for TECNIS® Symfony Extended Range of Vision Intraocular Lens for Cataract Patients investment picks
2014/7/16
- Second-Quarter Ongoing EPS of $0.54, Above Previous Guidance Range and Representing Double-Digit Earnings-Per-Share Growth - - GAAP EPS from Continuing Operations of $0.30 - - Raises Full-Year 2014 EPS Guidance Range - - Continues to Shape Abbott for Long-Term Growth with Agreements to Acquire CFR Pharmaceuticals and Veropharm, and to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - ABBOTT PARK, Ill., July 16, 2014 /PRNewswire/ -- Abbott today announced financial results for the second quarter ended June 30, 2014 .
Sign-up for Abbott Reports Second-Quarter 2014 Results investment picks
ABBOTT PARK, Ill., June 23, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer.
Sign-up for Abbott to Acquire Veropharm investment picks
Abbott will retain its branded generics pharmaceuticals business in emerging markets Transaction expected to positively impact Abbott's sales and ongoing earnings-per-share growth rates ABBOTT PARK, Ill., July 14, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company.
Sign-up for Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan investment picks
2014/7/28
ABBOTT PARK, Ill., July 28, 2014 /PRNewswire/ -- Clinical laboratories around the world are helping to improve patient care while navigating an evolving health care environment.
Sign-up for Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association for Clinical Chemistry Lab Expo investment picks
- Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer - AbbVie and Calico may co-invest up to $1.5 billion, utilizing Calico's discovery and early development capabilities and AbbVie's broad research, development and commercial expertise to advance innovative new therapies NORTH CHICAGO, Ill.
Sign-up for AbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies investment picks
- AbbVie will donate $10 to Cystic Fibrosis Research, Inc. (CFRI) for every recipe collected between August 1 and September 15, 2014, up to $10,000 - AbbVie will donate an additional $5,000 to CFRI if 50 recipes are submitted before Friday, August 8 - CFRI will provide educational resources and support for increasing awareness among patients on the importance of maintaining a proper CF diet NORTH CHICAGO , Ill.
Sign-up for AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program investment picks
- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations - Trial designed to evaluate veliparib as first-line therapy when added to DNA-damaging chemotherapy - Third Phase III trial initiated by AbbVie evaluating veliparib in difficult-to-treat tumor types NORTH CHICAGO, Ill.
Sign-up for AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) in Patients with Advanced Breast Cancer investment picks
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 - PIONEER I first Phase 3 trial to evaluate the investigational use of HUMIRA in patients with moderate-to-severe HS3 - Results show HUMIRA meets primary endpoint3 COPENHAGEN, Denmark , Sept.
Sign-up for AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease investment picks
LONDON (MarketWatch) -- U.S. drug maker AbbVie Inc. (ABBV) said on Friday it will buy Irish pharmaceutical firm Shire PLC (uk:shp) in a deal valued at $54 billion, a move that could release it from U.S. corporate taxes.
Sign-up for AbbVie confirms $54 billion merger with Shire investment picks
2014/8/18
- Recipients will compete for public votes for a chance to win one of two Thriving Undergraduate and Graduate Scholar awards - Supporters can vote for recipients at www.AbbVieCFScholarship.com NORTH CHICAGO, Ill.
Sign-up for AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie Declares Quarterly Dividend investment picks
2014/7/9
By Hester Plumridge AbbVie Inc.(ABBV) was forced Wednesday to retract statements it made the previous day on shareholder support for its $51.62 billion takeover offer for London-listed Shire PLC .
Sign-up for AbbVie forced to retract statements in $51 billion Shire bid investment picks
NEW YORK (MarketWatch) -- AbbVie Inc. (ABBV) said Wednesday its proposed offer for U.K. company Shire plc (uk:shrs) has a "compelling strategic rationale," and offers significant value to shareholders of both companies.
Sign-up for AbbVie makes its case for deal with Shire investment picks
2014/7/8
By Ian Walker LONDON--
Sign-up for AbbVie raises offer for Shire investment picks
NEW YORK (MarketWatch) -- AbbVie (ABBV) on Monday raised the midpoint of its 2014 earnings-per-share guidance by 6 cents to reflect a strong business performance in the year so far and expectations that a positive trend will continue through the rest of the year.
Sign-up for AbbVie raises outlook for 2014 investment picks
- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill.
Sign-up for AbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme investment picks
- Reports Second-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range of $0.75 to $0.77 (Reports GAAP EPS of $0.68) - Delivers Second-Quarter Revenue of $4.926 Billion, an Increase of 5.0 Percent Over Second-Quarter 2013 (Up 4.8 Percent On an Operational Basis); Revenue Up 12.3 Percent Operationally Excluding Lipid Sales Due to Loss of Exclusivity - Revenue Growth Reflects 26.2 Percent Global Reported Sales Growth from HUMIRA (Up 25.4 Percent On an Operational Basis) and Strong Growth from Other Key Products - Pipeline Continues to Advance Including Phase 3 Start for ABT-888, Positive Phase 3 Data for Daclizumab, Priority Review (FDA) and Accelerated Assessment (EMA) of our HCV Program, Positive Data from Next-Generation HCV Program and ABT-414 for Glioblastoma - Continues to Enhance the Company's Position and Shape AbbVie for the Long-Term with Agreement to Merge with Shire, Creating a Larger and More Diversified Biopharmaceutical Company and Driving
Sign-up for AbbVie Reports Second-Quarter 2014 Financial Results investment picks
2014/7/23
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Host Second-Quarter Earnings Conference Call investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Morgan Stanley Global Healthcare Conference investment picks
By Hester Plumridge LONDON --
Sign-up for AbbVie woes Shire into $54 billion acquisition deal investment picks
Abcam plc, a global leader in the manufacture and supply of innovative protein research tools and services, and Cell Marque Corporation, a provider of antibodies and reagents for diagnostic immunohistochemistry, announced today they have signed a global 10-year strategic marketing agreement for Abcam’s in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb ® primary antibody portfolio.
Sign-up for Abcam and Cell Marque Sign Global Strategic Marketing Agreement For IVD IHC RabMAb Antibodies investment picks
2014/8/12
Abcam plc, a global leader in the supply of innovative protein research tools, announced today it has established a direct service to Australia and New Zealand.
Sign-up for Abcam Establishes New Direct Service for Australia and New Zealand investment picks
2014/7/8
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0956218001&sourceType=1 http://www.ccnmatthews.com/logos/20110222-aben.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Aben Announces Exploration Program at Mann Lake Uranium Project in the Athabasca Basin, Saskatchewan investment picks
2014/8/26
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0964480001&sourceType=1 http://www.ccnmatthews.com/logos/20110222-aben.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Aben Commences Exploration Program at Mann Lake Uranium Project, Athabasca Basin, Saskatchewan investment picks
2014/7/10
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0956634001&sourceType=1 http://www.ccnmatthews.com/logos/20110222-aben.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Aben Resources Announces 2014 Exploration Program at Justin Gold-Silver-Tungsten Project, Southeast Yukon investment picks
2014/7/15
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0957637001&sourceType=1 http://www.ccnmatthews.com/logos/20110222-aben.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Aben Resources Arranges $100,000 Flow Through Financing investment picks
2014/7/28
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0959607001&sourceType=1 http://www.ccnmatthews.com/logos/20110222-aben.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Aben Resources Begins 2014 Exploration Program at Justin Gold-Silver-Tungsten Project, Southeast Yukon investment picks
2014/7/31
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0960533001&sourceType=1 http://www.ccnmatthews.com/logos/20110222-aben.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Aben Resources Closes $102,000 Flow Through Financing investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes to Aben Resources Closes $102,000 Flow Through Financing
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices